SCHEMBL3905283

SCHEMBL3905283

CN(C)C(C)(C)C(NC(=O)c1ccc(Cl)cc1Cl)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
TMEM97 Q5BJF2 2/20 0.47
SIGMAR1 Q99720 2/20 0.47
FLT1 P17948 3/20 0.45
FLT4 P35916 3/20 0.45
KDR P35968 3/20 0.45
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.44
P2RX7 Q99572 2/20 0.44
GPR27 Q9NS67 1/20 0.44
MAPT P10636 2/20 0.43
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CYP2C19 P33261 1/20 0.43
CTSL P07711 1/20 0.42
PSMB5 P28074 1/20 0.42
GPR139 Q6DWJ6 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903988 0.88 CTSL (0.44) MEN1KMT2AGAACTSL
SCHEMBL3901053 0.87 GPR139 (0.49) MEN1KMT2AALDH1A1P2RX7MAPT
SCHEMBL3901504 0.85 LMNA (0.43) ALDH1A1GAAGPR139THRBHTT
SCHEMBL3905178 0.83 POLB (0.42) MEN1KMT2AALDH1A1GPR27MAPT
SCHEMBL3902148 0.82 LMNA (0.44) MEN1KMT2AALDH1A1P2RX7MAPT
SCHEMBL3905654 0.81 LMNA (0.42) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL3907125 0.81 TAS1R3 (0.51) TMEM97SIGMAR1P2RX7NPC1RAB9A
SCHEMBL3905781 0.81 UTS2R (0.50) MEN1KMT2AALDH1A1MAPTNPC1
SCHEMBL3902170 0.80 LMNA (0.44) MEN1KMT2AALDH1A1P2RX7PSMB5
SCHEMBL3910586 0.79 CRHR1 (0.46) MEN1KMT2AALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP claimed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP disclosed
WO-2006067417-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS SLC18A2, SLC6A5, SLC1A2 MEN1 2710/4885KMT2A 1752/4885TMEM97 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.